Clinical trials: Attention-Deficit and Hyperactivity Disorder
Attention Deficit Disorder With Hyperactivity
Psychosocial Treatment for Attention Deficit Hyperactivity Disorder in Adults
This study will determine the effectiveness of group cognitive-behavioral therapy as compared to a problem-solving social support group in treating problems of time management, organization, and planning in adults with attention…
- Trial name
- NCT00278473
- Testing
- Meta-Cognitive Therapy, Supportive Therapy
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Attention-Deficit/Hyperactivity Disorder
Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD
Open label, flexible dose, long-term multicenter study of safety and efficacy of SPN-812 in adult ADHD patients
- Trial name
- NCT04143217
- Testing
- SPN-812
- Where
- 38 sites in United States
- Volunteers
- 159 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Traumatic Brain Injury, TBI
Methylphenidate for Attention Problems After Pediatric TBI
Traumatic Brain Injury (TBI) - methylphenidate treatment
- Conditions
- Traumatic Brain Injury, TBI, ADHD
- Trial name
- NCT01933217
- Testing
- Methylphenidate
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Attention Deficit Hyperactivity Disorder (ADHD)
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of SPN-810 in the treatment of Impulsive Aggression (IA) in subjects with Attention-Deficit/Hyperactivity Disorder (ADHD) in conjunction with…
- Trial name
- NCT02618408
- Testing
- SPN-810 (18 mg), SPN-810 (36 mg)
- Where
- 28 sites in United States
- Volunteers
- 333 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Huntington Disease, Chorea
Atomoxetine and Huntington's Disease
The purpose of this research study is to evaluate the effect of atomoxetine (also known as Strattera) compared to placebo (inactive substance) on daily activities such as attention and focus, thinking ability and muscle movements…
- Trial name
- NCT00368849
- Testing
- atomoxetine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Iowa
Attention-deficit/Hyperactivity Disorder
Examining Tolerance to CNS Stimulants in ADHD
Although stimulant medication is a well-established treatment for ADHD, it is often necessary for doctors to increase the dose over time to maintain the benefits of the medication.
- Trial name
- NCT02039908
- Testing
- Methylphenidate
- Where
- United States
- Volunteers
- 267 people
- Sponsor
- Florida International University
Attention Deficit Hyperactivity Disorder, ADHD
Imaging Stimulant and Non Stimulant Treatments for ADHD: A Network Based Approach
The growing number of medications used to treat attention-deficit/hyperactivity disorder (ADHD) raises important questions about whether different medications have similar or different therapeutic mechanisms of action.
- Trial name
- NCT01678209
- Testing
- fMRI scans, Atomoxetine arm, Methylphenidate arm
- Where
- United States
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Attention Deficit Hyperactivity Disorder
A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)
The main aim of this study is learn more about long-term TAK-503 treatment in children and teenagers with ADHD for whom earlier stimulant treatment did not work. The study has two parts (A and B).
- Trial name
- NCT04085172
- Testing
- Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride
- Where
- 50 sites in United States, Austria and 7 more
- Volunteers
- 396 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder
A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder
The primary purpose of the study is to assess long-term safety and tolerability of Edivoxetine in pediatric participants with attention deficit hyperactive disorder (ADHD).
- Trial name
- NCT00965419
- Testing
- Edivoxetine
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 267 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
Cognitive ADHD Videogame Exploratory Study
A study in ADHD and neuro-typical children to assess EVO game play over 29 days.
- Trial name
- CAVES (NCT01943539)
- Testing
- Neuro-typical controls and ADHD will receive EVO game play.
- Where
- 2 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Akili Interactive Labs, Inc.
ADHD
Nicotine and Behavior in Adult ADHD
Attention deficit hyperactivity disorder (ADHD) is characterized by inattention, impulsivity, and hyperactivity that are frequently treated with stimulant medications such as Ritalin. Many people with ADHD smoke.
- Trial name
- NCT00573248
- Testing
- Nicotine
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- University of California, Irvine
Attention Deficit Hyperactivity Disorder
Should Chronic Stimulant Medications be Continued Preoperatively in Patients With Attention Deficit Hyperactivity Disorder(ADHD)
Patients on chronic stimulant therapy for the treatment of Attention deficit hyperactivity disorder (ADHD) who are undergoing an outpatient surgical or diagnostic procedure will be randomized to one of two groups: stimulant…
- Trial name
- NCT01740206
- Testing
- Amphetamine and/or methylphenidate, Hold stimulant medication
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Nationwide Children's Hospital
Attention Deficit Hyperactivity Disorder
Study of the Effects of Osmotic-Release Oral System (OROS) Methylphenidate (Concerta) on Attention and Memory
This study investigates whether OROS-methylphenidate improves performance on different aspects of attention and memory in children with Attention-Deficit Hyperactivity Disorder (ADHD).
- Trial name
- CHOP (NCT00530257)
- Testing
- OROS-methylphenidate
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Children's Hospital of Philadelphia
Attention Deficit Hyperactivity Disorder (ADHD)
Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)
The study is designed to evaluate the efficacy and safety of each dose of SHP465 (12.5 and 37.5 mg) given to participants daily in the morning compared to placebo in the treatment of adults aged 18 to 55 years diagnosed with ADHD.
- Trial name
- NCT02604407
- Testing
- SHP465 12.5mg capsules (one capsule daily), SHP465 12.5mg, 25mg, or 37.5mg capsules (one capsule daily)
- Where
- 45 sites in United States
- Volunteers
- 275 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder
Study to Evaluate the Efficacy and Quality of Life of Long-Acting Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the efficacy, safety and to assess the impact of the treatment on quality of life of long-acting methylphenidate in adult participants with Attention Deficit Hyperactivity Disorder (ADHD).
- Trial name
- NCT00783835
- Testing
- Long-Acting Methylphenidate
- Where
- 5 sites in Brazil
- Volunteers
- 60 people
- Sponsor
- Janssen-Cilag Farmaceutica Ltda.
Attention Deficit Hyperactivity Disorder (ADHD)
Four-week Open-trial Extension TNS for ADHD
The purpose of this study will be to offer children previously randomized to sham treatment in a 5-week double-blind sham controlled study of Trigeminal Nerve Stimulation for ADHD (NCT02155608) an opportunity to receive 4-weeks…
- Trial name
- NCT03870737
- Testing
- Active TNS
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of California, Los Angeles
Attention Deficit/ Hyperactivity Disorder
A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder
The purpose of this study is to evaluate the efficacy of 2 fixed dosages of Prolonged Release (PR) OROS methylphenidate (54 and 72 mg/day) compared with placebo in adult patients with attention deficit/hyperactivity disorder…
- Trial name
- NCT00714688
- Testing
- prolonged release (PR) OROS methylphenidate 54 mg, prolonged release (PR) OROS methylphenidate 72 mg
- Where
- 42 sites in Belgium, Denmark and 9 more
- Volunteers
- 279 people
- Sponsor
- Janssen-Cilag International NV
Attention Deficit Hyperactivity Disorder
Impact of Strattera and Behavior Therapy on the Home and School Functioning of Children With ADHD
Background: Multiple studies have found Atomoxetine (Strattera) to be efficacious but there is only one published study specifically designed to evaluate its efficacy in school settings.
- Trial name
- NCT00918567
- Testing
- atomoxetine, Behavior Modification Therapy
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- State University of New York at Buffalo
Attention-Deficit/Hyperactivity Disorder (ADHD)
A Study to Test the Safety and Efficacy of MK0249 in Patients With ADHD (0249-018)(COMPLETED)
The purpose of this study is to investigate the safety and efficacy of an investigational treatment for Attention Deficit Hyperactivity Disorder (ADHD) when compared to placebo.
- Trial name
- NCT00475735
- Testing
- MK0249, Concerta (methylphenidate)
- Volunteers
- 72 people
- Sponsor
- Merck Sharp & Dohme LLC
Attention Deficit Hyperactivity Disorder
Development of a Multi-faceted Cognitive Training Program for Children With Attention Deficit Hyperactivity Disorder (ADHD)
After decades of Attention Deficit Hyperactivity Disorder (ADHD) intervention research, only two intervention approaches (i.e., psychopharmacology, behavioral treatment) have a "well-established" evidence-base supporting their…
- Trial name
- NCT01352468
- Testing
- Multifaceted cognitive training
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati